MedTrace Logo

Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain

NCT01327326 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-07-13

No results posted yet for this study

Summary

The aim of this proposal is to characterize pain inhibition in healthy controls and Temporomandibular Disorder (TMD) patients with two models of endogenous pain modulation (off-set analgesia; conditioned pain modulation), and to investigate the function of the endogenous opioid system in these responses by using pharmacological blockade of the opioid receptor.

Conditions

  • Temporomandibular Disorder
  • Facial Pain

Interventions

DRUG

Naltrexone

Oral, 50 mg, 1 Time Dose

DRUG

Placebo

Oral, 1 Time Dose

Sponsors & Collaborators

  • American Pain Society

    collaborator OTHER

  • University of Florida

    lead OTHER

Principal Investigators

  • Christopher D King, PhD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327326 on ClinicalTrials.gov